# The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

> **NCT06958627** · PHASE2,PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 964 (estimated)

## Conditions studied

- HER2 Positive Breast Cancer
- Pyrotinib Treatment

## Interventions

- **DRUG:** pyrotinib

## Key facts

- **NCT ID:** NCT06958627
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2025-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 964 (ESTIMATED)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958627, "The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT06958627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*